Video
Author(s):
Adam Scott Feldman, MD, MPH, urologist at Massachusetts General Hospital, assistant professor of Surgery, Harvard Medical School, discusses a study focused on active surveillance in men with prostate cancer under the age of 60.
Adam Scott Feldman, MD, MPH, urologist at Massachusetts General Hospital, assistant professor of Surgery, Harvard Medical School, discusses a study focused on active surveillance in men with prostate cancer under the age of 60.
For men with low- to intermediate-risk prostate cancer, active surveillance is an option for attempting to avoid treatment. There is a study that focused on active surveillance in men under 60 years old. Historically, active surveillance has been avoided in younger men for the concern that they will eventually need treatment or harbor a more aggressive disease.
In this study, there were 432 men with a median age of 55 years. The median time of follow-up was 5.1 years.